In plain language
Hexarelin is a synthetic growth hormone releasing peptide that strongly stimulates growth hormone through the ghrelin receptor and also interacts with a separate cardiac receptor in research. It is one of the more potent secretagogues studied but is not an approved medicine, and evidence for wellness uses is limited.
What it is explored for
Hexarelin is one of the more potent growth hormone releasing peptides studied, and its separate interaction with the CD36 receptor has sparked preclinical interest in heart-related effects. It is a genuinely interesting molecule, though controlled human trials for wellness uses are limited and the GH response can fade with repeated dosing, so the evidence stays early. Here is where interest is highest.
- Stimulating natural growth hormone release
- Recovery and lean-mass interest
- Cardiovascular research via CD36
- Pairing with GHRH analogs
- Growth hormone pharmacology research
These are areas of active interest and reported use, not proven outcomes. This peptide carries a limited evidence rating, see the evidence summary below for how strong the science actually is.
How it works
Hexarelin activates the growth hormone secretagogue (ghrelin) receptor to release growth hormone, and in research it also binds the CD36 scavenger receptor, which has been studied for separate cardiovascular effects.
- Ghrelin receptor agonism. Potently stimulates the GHS receptor to trigger growth hormone release.
- CD36 binding. In animal studies it binds the CD36 receptor, which researchers have explored for cardioprotective effects independent of GH.
- Potential desensitization. With repeated dosing the GH response may diminish over time, a tolerance effect noted in some studies.
Cardiac and desensitization observations come largely from animal and early human work; clinical outcomes in people are not established.
Evidence summary
Hexarelin is among the more potent GH-releasing peptides in early human pharmacology, and its CD36 interaction has prompted preclinical cardiovascular interest. However, there are no published, well-controlled trials supporting marketed wellness or performance uses, and receptor desensitization with repeated dosing is a recognized limitation.
Reported safety & side effects
Short-term studies describe it as generally tolerated, with flushing and modest rises in cortisol and prolactin among reported effects. Long-term human safety and the consequences of desensitization are not established.
Stacking notes
Full stacking guideMK-677 already raises growth hormone and IGF-1 strongly on its own. Adding another secretagogue compounds water retention, appetite, and insulin-resistance effects for little clear added benefit.
MK-677IpamorelinStacking two peptides that hit the same ghrelin receptor (for example ipamorelin with GHRP-6 or hexarelin) is largely redundant and increases hunger, cortisol, and prolactin without a clear reason.
IpamorelinGHRP-6General educational guidance, not medical advice. Combination evidence is limited; any stack should involve a qualified clinician.
Frequently asked
Is hexarelin FDA-approved?
No. Hexarelin is not approved by the FDA for any use. It is sold as a research chemical and is not an approved medicine.
What makes hexarelin different from other GHRPs?
It is one of the most potent GH releasers in its class and also binds the CD36 receptor, which has drawn separate research interest for possible cardiovascular effects. It is also noted for potential desensitization with repeated use.
Does the growth hormone effect last with ongoing use?
Not necessarily. Some studies report that the GH response to hexarelin can diminish over time with repeated dosing, a tolerance effect that is one reason its long-term value is uncertain.